Haneen Shalabi1, Staci Martin1, Bonnie Yates1, Pamela L Wolters1, Claire Kaplan1, Hannah Smith1, Christopher R Sesi1, Jennifer Jess1, Mary Anne Toledo-Tamula2, Kari Struemph2, Cindy P Delbrook1, Omar I Khan3, Crystal L Mackall1,4,5,6, Daniel W Lee1,7,8, Nirali N Shah1. 1. Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA. 2. Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, USA. 3. National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. 4. Center for Cancer Cell Therapy, Stanford Cancer Institute, Palo Alto, California, USA. 5. Department of Pediatrics, Stanford University, Palo Alto, California, USA. 6. Department of Medicine, Stanford University, Palo Alto, California, USA. 7. Department of Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, Virginia, USA. 8. University of Virginia Cancer Center, Charlottesville, Virginia, USA.
Abstract
BACKGROUND: Neurotoxicity is an established toxicity of CD19 CAR T-cell therapy; however, there is little information on neurotoxicity in children, adolescents, and young adults (CAYA) receiving CD19/CD28ζ CAR T-cells for B-cell malignancies. METHODS: We analyzed neurotoxicity of CD19/CD28ζ CAR T-cells in CAYA treated on a phase I study (NCT01593696). Assessments included daily inpatient monitoring, caregiver-based neuro-symptom checklist (NSC), exploratory neurocognitive assessments, clinically-indicated imaging, CSF analysis, and systematic cytokine profiling, outcomes of which were associated with cytokine release syndrome (CRS) and treatment response postinfusion. Patients with active CNS leukemia were included. RESULTS: Amongst 52 patients treated, 13 patients had active CNS leukemia at infusion. Neurotoxicity was seen in 11/52 (21.2%) patients, with an incidence of 29.7% (11/37) in patients with CRS. Neurotoxicity was associated with the presence and severity of CRS. Those with neurotoxicity had higher levels of peak serum IL-6, IFNγ, and IL-15. Additionally, CNS leukemia was effectively eradicated in most patients with CRS. Pilot neurocognitive testing demonstrated stable-to-improved neurocognitive test scores in most patients, albeit limited by small patient numbers. The NSC enabled caregiver input into the patient experience. CONCLUSIONS: This is the first systematic analysis of neurotoxicity utilizing a CD19/CD28ζ CAR construct in CAYA, including in those with active CNS involvement. The experience demonstrates that the neurotoxicity profile was acceptable and reversible, with evidence of anti-leukemia response and CNS trafficking of CAR T-cells. Additionally, neurocognitive testing, while exploratory, provides an opportunity for future studies to employ systematic evaluations into neurotoxicity assessments and validation is needed in future studies. Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2022.
BACKGROUND: Neurotoxicity is an established toxicity of CD19 CAR T-cell therapy; however, there is little information on neurotoxicity in children, adolescents, and young adults (CAYA) receiving CD19/CD28ζ CAR T-cells for B-cell malignancies. METHODS: We analyzed neurotoxicity of CD19/CD28ζ CAR T-cells in CAYA treated on a phase I study (NCT01593696). Assessments included daily inpatient monitoring, caregiver-based neuro-symptom checklist (NSC), exploratory neurocognitive assessments, clinically-indicated imaging, CSF analysis, and systematic cytokine profiling, outcomes of which were associated with cytokine release syndrome (CRS) and treatment response postinfusion. Patients with active CNS leukemia were included. RESULTS: Amongst 52 patients treated, 13 patients had active CNS leukemia at infusion. Neurotoxicity was seen in 11/52 (21.2%) patients, with an incidence of 29.7% (11/37) in patients with CRS. Neurotoxicity was associated with the presence and severity of CRS. Those with neurotoxicity had higher levels of peak serum IL-6, IFNγ, and IL-15. Additionally, CNS leukemia was effectively eradicated in most patients with CRS. Pilot neurocognitive testing demonstrated stable-to-improved neurocognitive test scores in most patients, albeit limited by small patient numbers. The NSC enabled caregiver input into the patient experience. CONCLUSIONS: This is the first systematic analysis of neurotoxicity utilizing a CD19/CD28ζ CAR construct in CAYA, including in those with active CNS involvement. The experience demonstrates that the neurotoxicity profile was acceptable and reversible, with evidence of anti-leukemia response and CNS trafficking of CAR T-cells. Additionally, neurocognitive testing, while exploratory, provides an opportunity for future studies to employ systematic evaluations into neurotoxicity assessments and validation is needed in future studies. Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2022.
Entities:
Keywords:
CAR T-cell; cytokine release syndrome; neurotoxicity
Authors: Rebecca A Gardner; Olivia Finney; Colleen Annesley; Hannah Brakke; Corinne Summers; Kasey Leger; Marie Bleakley; Christopher Brown; Stephanie Mgebroff; Karen S Kelly-Spratt; Virginia Hoglund; Catherine Lindgren; Assaf P Oron; Daniel Li; Stanley R Riddell; Julie R Park; Michael C Jensen Journal: Blood Date: 2017-04-13 Impact factor: 22.113
Authors: Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall Journal: Lancet Date: 2014-10-13 Impact factor: 79.321
Authors: Agne Taraseviciute; Victor Tkachev; Rafael Ponce; Cameron J Turtle; Jessica M Snyder; H Denny Liggitt; David Myerson; Luis Gonzalez-Cuyar; Audrey Baldessari; Chris English; Alison Yu; Hengqi Zheng; Scott N Furlan; Daniel J Hunt; Virginia Hoglund; Olivia Finney; Hannah Brakke; Bruce R Blazar; Carolina Berger; Stanley R Riddell; Rebecca Gardner; Leslie S Kean; Michael C Jensen Journal: Cancer Discov Date: 2018-03-21 Impact factor: 39.397
Authors: Kevin R Parker; Denis Migliorini; Eric Perkey; Kathryn E Yost; Aparna Bhaduri; Puneet Bagga; Mohammad Haris; Neil E Wilson; Fang Liu; Khatuna Gabunia; John Scholler; Thomas J Montine; Vijay G Bhoj; Ravinder Reddy; Suyash Mohan; Ivan Maillard; Arnold R Kriegstein; Carl H June; Howard Y Chang; Avery D Posey; Ansuman T Satpathy Journal: Cell Date: 2020-09-21 Impact factor: 41.582
Authors: Andrea M Gross; Pamela L Wolters; Eva Dombi; Andrea Baldwin; Patricia Whitcomb; Michael J Fisher; Brian Weiss; AeRang Kim; Miriam Bornhorst; Amish C Shah; Staci Martin; Marie C Roderick; Dominique C Pichard; Amanda Carbonell; Scott M Paul; Janet Therrien; Oxana Kapustina; Kara Heisey; D Wade Clapp; Chi Zhang; Cody J Peer; William D Figg; Malcolm Smith; John Glod; Jaishri O Blakeley; Seth M Steinberg; David J Venzon; L Austin Doyle; Brigitte C Widemann Journal: N Engl J Med Date: 2020-03-18 Impact factor: 91.245
Authors: Haneen Shalabi; Pamela L Wolters; Staci Martin; Mary Anne Toledo-Tamula; Marie Claire Roderick; Kari Struemph; Eli Kane; Bonnie Yates; Cindy Delbrook; Crystal L Mackall; Daniel W Lee; Terry J Fry; Nirali N Shah Journal: J Immunother Date: 2018-09 Impact factor: 4.456